Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294784" target="_blank" >RIV/00216208:11110/15:10294784 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/15:10294784
Result on the web
<a href="http://dx.doi.org/10.1111/ene.12618" target="_blank" >http://dx.doi.org/10.1111/ene.12618</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ene.12618" target="_blank" >10.1111/ene.12618</a>
Alternative languages
Result language
angličtina
Original language name
Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
Original language description
Background and purposeImpaired ambulation is a prominent disabling symptom of multiple sclerosis and can lead to reduced quality of life. Whether natalizumab, a monoclonal antibody shown to reduce disease activity in relapsing-remitting multiple sclerosis, could impact ambulation performance was examined. MethodsA prospective open-label study, TIMER, was conducted in natalizumab-naive patients (n=215). The timed 25-foot walk (T25FW) and timed 100-m walk (T100MW) were assessed at baseline and at weeks 24and 48 of natalizumab therapy, together with Expanded Disability Status Scale scores. The effects of natalizumab on T25FW performance were also examined in a retrospective analysis of natalizumab-treated patients (n=627) and placebo control patients (n=315) from the AFFIRM study. ResultsIn TIMER, a significant increase from baseline in T25FW speed was seen at week 24 (P=0.0074) and in T100MW speed at weeks 24 and 48 (both P<0.001). A greater proportion of patients showed clinically mean
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Neurology
ISSN
1351-5101
e-ISSN
—
Volume of the periodical
22
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
570-577
UT code for WoS article
000349676000023
EID of the result in the Scopus database
2-s2.0-84922727144